0.3013
전일 마감가:
$0.3098
열려 있는:
$0.3126
하루 거래량:
962.12K
Relative Volume:
0.93
시가총액:
$19.47M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-0.3814
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+0.43%
1개월 성능:
+26.07%
6개월 성능:
-57.04%
1년 성능:
-81.96%
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2403 SIDNEY STREET, PITTSBURGH
CGTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CGTX
Cognition Therapeutics Inc
|
0.3012 | 19.47M | 0 | -22.83M | -20.87M | -0.79 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.48 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
536.76 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
552.05 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2021-11-03 | 개시 | B. Riley Securities | Buy |
2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Two Sigma Investments LP Boosts Stock Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Cognition Therapeutics (CGTX) Secures Donation to Support Dement - GuruFocus
Cognition Therapeutics Launches Expanded Access Program for Zervimesine - TipRanks
Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin - Nasdaq
Philanthropic Donor Funds Cognition Therapeutics’ Expanded - GlobeNewswire
Major Breakthrough: Donor Funds New Treatment Access for Lewy Body Dementia Patients - Stock Titan
B. Riley Expects Reduced Earnings for Cognition Therapeutics - Defense World
HC Wainwright Issues Positive Forecast for CGTX Earnings - Defense World
Alzheimer's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Lewy Body Dementia Caregivers Share Powerful Stories Alongside Leading Neurologists in New Medical Podcast - Stock Titan
CGTX: HC Wainwright & Co. Lowers Price Target While Maintaining Buy Rating | CGTX Stock News - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Exp - GuruFocus
Cognition Therapeutics (CGTX) Sees Reduced Price Target Amid Expected Equity Dilution | CGTX Stock News - GuruFocus
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times
zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive
Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log
Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com
Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus
COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph
Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader
Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com
Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):